SCHEMBL4968847

SCHEMBL4968847

Cc1cc(NC(=O)c2ccccc2N)ccc1C(=O)O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.65
NPC1 O15118 3/20 0.58
RAB9A P51151 3/20 0.58
KDM4E B2RXH2 1/20 0.58
CASP3 P42574 1/20 0.58
SENP8 Q96LD8 1/20 0.58
HSD17B10 Q99714 1/20 0.58
SENP7 Q9BQF6 1/20 0.58
SENP6 Q9GZR1 1/20 0.58
ALDH1A1 P00352 2/20 0.57
KMT2A Q03164 2/20 0.57
MEN1 O00255 1/20 0.57
FADS1 O60427 3/20 0.56
PTGS1 P23219 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
P2RX1 P51575 1/20 0.51
MAPK13 O15264 1/20 0.51
MAPK12 P53778 1/20 0.51
MAPK11 Q15759 1/20 0.51
MAPK14 Q16539 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31424204 0.87 CYP1A2 (0.70) CYP1A2NPC1RAB9AALDH1A1KMT2A
SCHEMBL533724 0.87 CYP1A2 (0.70) CYP1A2NPC1RAB9AALDH1A1KMT2A
SCHEMBL22025347 0.87 FADS1 (0.59) CYP1A2NPC1RAB9AKDM4ECASP3
SCHEMBL1963977 0.87 CYP1A2 (0.70) CYP1A2NPC1RAB9AALDH1A1KMT2A
SCHEMBL22065324 0.82 FADS1 (0.54) CYP1A2NPC1RAB9AKDM4ECASP3
SCHEMBL5666204 0.80 FADS1 (0.67) CYP1A2NPC1RAB9AHSD17B10ALDH1A1
SCHEMBL4954215 0.80 PTGS1 (0.67) NPC1RAB9AKDM4ECASP3SENP8
SCHEMBL17744848 0.79 PTGS1 (0.75) NPC1RAB9AKDM4ECASP3SENP8
SCHEMBL259352 0.79 MEN1 (0.72) NPC1RAB9AKDM4ECASP3SENP8
SCHEMBL31424193 0.79 MEN1 (0.72) NPC1RAB9AKDM4ECASP3SENP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008094909-A2 QUINAZOLINONE AND FUSED PYRIMIDINONE COMPOUNDS AND THEIR USE IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS XENON PHARMACEUTICALS INC. (CA) 2008-08-07 WO disclosed